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ABSTRACT
Rheumatoid arthritis (RA) is a chronic systemic
autoimmune condition which affects
approximately 1% of the adult population
worldwide and is characterized by joint
inflammation, with extra-articular features
being common. Interleukin 6 (IL-6) is one of
the chief pro-inflammatory cytokines found in
the joints and sera of patients with RA.
Increased levels of IL-6 correlate with
inflammation, disease activity, and
radiological damage. RA treatment should
focus on minimizing the signs and symptoms
of disease (pain, stiffness, and swelling of the
joints) and on preventing or minimizing joint
damage to preserve functionality and quality of
life. The benefits of early, intensive intervention
are now acknowledged, with all patients with
newly diagnosed, active RA being started on
methotrexate (MTX) monotherapy or
combination therapy. Lack of efficacy,
intolerance, and/or toxicity can lead to
discontinuation of this drug, and there is a
need for exploring further treatment options. In
the UK, patients with persistently high disease
activity who have failed at least two
conventional disease-modifying agents
(DMARDs) including MTX may qualify for
biologic therapy. Numerous trials have shown
intravenous (IV) tocilizumab (TCZ), a biologic
drug targeting and inhibiting IL-6, to be
effective for controlling inflammation in RA,
with an acceptable safety profile. Its superiority
in monotherapy when compared with other
biologic agents makes it the drug of choice for
patients who are intolerant or have
contraindications to traditional DMARDs.
However, one of the drawbacks of IV TCZ is
the requirement for monthly infusions, which
is inherently inconvenient for the patient and
associated with increased cost. Subcutaneous
(SC) TCZ has now been approved following two
clinical trials which showed similar efficacy and
safety compared to IV TCZ, and better efficacy
compared to placebo (SUMMACTA and
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BREVACTA trials, respectively). Respiratory
infections are the most common side effects in
patients receiving SC TCZ. Advantages of SC
formulations include convenience and reduced
cost compared with IV therapies. Overall,
patients tend to have a preference for SC over
IV administration of medications. Close
monitoring of patients should be undertaken
in all cases, paying particular attention to the






Rheumatoid arthritis (RA) is a chronic systemic
autoimmune condition characterized by joint
inflammation, although extra-articular features
are common. RA affects approximately 1% of
the adult population worldwide and is more
common in women [1, 2]. The incidence of RA
in the UK is 36 per 100,000 women and 14 per
100,000 men per year [1, 2] and RA may lead to
significant disability, reduced quality of life,
and increased mortality [1, 3–5]. Furthermore, it
has a significant impact on work productivity,
with approximately one-third of patients
having to leave employment within 2 years of
diagnosis [6].
Joint Involvement in Rheumatoid
Arthritis
Although typically a disease of the hands and
feet, RA may affect any synovial joint.
Inflammation of the synovium, followed by
progressive degradation of cartilage and
subsequent bone erosion are the hallmark of
active untreated disease.
Systemic Effects of Rheumatoid Arthritis
In addition to joint destruction, RA can result in
a variety of extra-articular manifestations
including anemia, localized and generalized
osteoporosis [7, 8], nodulosis, eye disease, and
pulmonary and cardiovascular (CV) disease [9,
10]. Being diagnosed with RA is an independent
risk factor for atherosclerosis (similar in severity
to type 2 diabetes mellitus) due to chronic,
systemic inflammation [11–13]. CV disease has
emerged as the number one cause of mortality
in patients with RA [14, 15].
Immunopathogenesis
The articular and extra-articular manifestations
of RA are caused at a molecular level by
increased levels of pro-inflammatory cells,
cytokines, and autoantibody production [8].
Pro-inflammatory cytokines, such as tumor
necrosis factor alpha (TNF-a), interleukin 1 (IL-
1), interleukin 6 (IL-6), interleukin 17 (IL-17),
interferon gamma (IFN-c), and transforming
growth factor beta (TGF-b), can stimulate the
release of further cytokines [16–19], leading to
excessive cellular activation and migration into
the synovium and sustained inflammation [16,
17, 19].
THE ROLE OF IL-6 IN RHEUMATOID
ARTHRITIS
IL-6 is one of the chief pro-inflammatory
cytokines found in the joints and sera of
patients with RA [20–23]. A number of cell
types produce and release IL-6, including
activated macrophages, synovial fibroblasts,
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and T and B cells [8, 24–26]. Increased levels of
IL-6 correlate with inflammation, disease
activity, and radiological damage [8, 24, 27–
30]. Furthermore, the decrease in serum IL-6
levels in the first 12 months of therapy with
disease-modifying agents (DMARDs) is a






Treatment for RA should focus on minimizing
the signs and symptoms of the disease (pain,
stiffness, and swelling of the joints) and on
preventing or minimizing joint damage to
preserve functionality and quality of life. In
addition, reducing the extra-articular
manifestations and implicitly reducing the
premature mortality associated with the
condition is critical [31, 32].
Suppression of inflammation is the central
element of RA management, with remission
(defined as the complete suppression of
inflammation and prevention of joint
destruction) being the ultimate goal of
therapy [16, 19, 33]. Non-steroidal anti-
inflammatory drugs (NSAIDs) may provide
fast and effective relief of symptoms, but do
not alter the disease course. The cornerstone
of therapy, therefore, is DMARDs, which
should be instituted as early as possible to
prevent long-term joint damage [34–36]. For
safety and efficacy reasons, patients should be
frequently monitored and treatment altered
accordingly, adopting a treat to target
strategy [37].
Although highly effective in many cases,
traditional DMARDs [such as methotrexate
(MTX), sulfasalazine (SSZ), leflunomide (LEF),
and hydroxychloroquine (HCQ)] can be
associated with toxicity and/or intolerability,
with a high impact on adherence and thus on
disease control [38–41].
The benefits of early, intensive intervention
are now acknowledged, with all patients with
newly diagnosed, active RA being started on
MTX monotherapy or combination therapy
(usually with HCQ). The pre-eminent DMARD
is MTX; however, lack of efficacy, intolerance,
and/or toxicity can lead to discontinuation [40],
and with it the need of exploring further
treatment options.
Biologic Agents
Biologic agents target specific pro-inflammatory
cytokines, cells, or molecules involved in the
pathogenesis of RA [16]. Five anti-TNF-a
therapies (infliximab, adalimumab, etanercept,
certolizumab, and golimumab) are currently
licensed in Europe and the USA [16, 19].
Although TNF-inhibitors have revolutionized
RA treatment over the last decade or so, there
remains an area of unmet need, with up to 40%
of patients failing to respond to this particular
treatment [16, 19, 42]. Other disadvantages of
TNF-a inhibitors include contraindications such
as heart failure, chronic or recurrent infections,
and demyelinating conditions, as well as side
effects that can lead to treatment
discontinuation (serious infections, injection
site reactions (ISR), melanoma, non-melanoma
skin malignancies [43], and lupus-like illness).
Reactivation of latent tuberculosis (TB)
infection may occur; however, this has been
minimized by screening programs and the use
of prophylactic anti-TB agents in those at risk.
Due to the area of unmet needs, other
biologic agents have been trialed in RA.
Anakinra, an IL-1 inhibitor, was one of the
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first biologics studied in RA [44]; however, it is
no longer used due to its lower efficacy
compared with other agents and the poor
tolerability of daily subcutaneous (SC)
injections. Rituximab (RTX), an anti-CD20
found on B cells, is now well established for
the treatment of RA [45]. Further biologic
agents include abatacept which inhibits the
co-stimulation of T cells [46], and tocilizumab
(TCZ), an IL-6 receptor antagonist [47]. Whereas
RTX is administered by intravenous (IV)
infusion no less frequently than 6 monthly,
the latter two agents were initially administered
as IV infusions; however, SC formulations are
now available [48–51]. This article will
specifically focus on SC TCZ including its
safety, efficacy, and how it may fit in RA
treatment regimens. Furthermore, this article
is based on previously conducted studies and
does not involve any new studies of human or





Numerous trials have shown IV TCZ to be an
effective drug for controlling inflammation in
RA with an acceptable safety profile [47, 52–56].
Its superiority in monotherapy when compared
with other biologic agents makes it the drug of
choice for patients who are intolerant or have
contraindications to traditional DMARDs [36].
However, one of the drawbacks of IV TCZ is the
requirement for monthly infusions with the
inherent inconvenience for the patient and
cost. Two phase III clinical trials have led to
the approval of SC TCZ, having shown the
efficacy and tolerability of SC TCZ in RA [50,
51].
The SUMMACTA trial (ClinicalTrials.gov
#NCT01194414) compared SC and IV TCZ and
met its primary end point, showing that TCZ SC
162 mg weekly is non-inferior to TCZ IV 8 mg/
kg in terms of efficacy [50]. The American
College of Rheumatology 20 (ACR 20)
response was achieved in 69.4% of patients at
week 24 in the TCZ SC group, compared with
73.4% in the TCZ IV group. The difference of
-4.0% (95% confidence interval [CI] -9.2 to
1.2) met the requirement for the non-inferiority
of TCZ SC to TCZ IV. The ACR 50 and ACR 70
response rates at 24 weeks were also similar
between groups (weighted differences of ACR 50
and ACR 70 responders at week 24: -1.8 and
-3.8%, respectively).
Disease Activity Score in 28 Joints (DAS 28)
remission was another clinical outcome
measured in the SUMMACTA trial [50]. The
proportion of patients who achieved DAS 28
remission at week 24 was similar in both SC and
IV groups, with a weighted difference of 0.9%.
The non-inferiority of SC TCZ to IV TCZ was
also demonstrated for functionality outcomes,
with a weighted difference of -2.3% in the
proportion of patients achieving a decrease of
0.3 or greater in Health Assessment
Questionnaire Disability Index (HAQ-DI) from
baseline (Fig. 1).
The BREVACTA trial (ClinicalTrials.gov
#NCT01232569) studied the efficacy and
safety of SC TCZ compared to SC placebo in
patients with RA who had an inadequate
response to traditional DMARDs [51]. The
study met its primary end point, showing
the superiority of SC TCZ (162 mg every
2 weeks) to SC placebo in achieving ACR 20
response at week 24 [60.9 and 31.5%,
respectively; weighted difference 29.5% [95%
CI 22.0–37.0; P\0.0001]). In a similar trend,
ACR 50 and ACR 70 response rates at week 24
were significantly higher in the SC TCZ group
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(27.9% [95% CI 21.5–34.4; P\0.0001] and
14.8% [95% CI 9.8–19.9; P\0.0001],
respectively). DAS 28 remission (defined as
DAS 28\2.6) was significantly higher at week
24 in the SC TCZ group compared to the
placebo group (weighted difference 28.6%
[95% CI 22.5–35.2; P\0.0001]). The mean
change from baseline at week 24 in the total
Sharpe score was lower in the SC TCZ group
compared to the placebo group (0.62 ± 2.692
vs. 1.23 ± 2.816), with a significant difference
in the erosion score and a non-statistically




The safety of SC TCZ was also assessed in the
SUMMACTA (Table 1) and BREVACTA studies.
Fig. 1 Disease activity and physical function over 24 weeks
for patients in the per-protocol (PP) population.
a Proportion of patients in the PP population treated with
either subcutaneous tocilizumab (TCZ SC; n = 558) or
intravenous tocilizumab (TCZ IV; n = 537) achieving 20,
50, and 70% improvements per American College of
Rheumatology criteria (ACR20, ACR50, and ACR70,
respectively) over 24 weeks. b Proportion of patients
achieving remission based on disease activity score using
28 joints (DAS 28) based on erythrocyte sedimentation rate
(ESR \2.6) over 24 weeks. c Proportion of patients
achieving a health assessment questionnaire (HAQ)
response (improvement of C0.3 from baseline) over
24 weeks. Reproduced from: Burmester et al. [50] with
permission from BMJ Publishing Group Ltd. qw weekly
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In the SUMMACTA trial a similar safety profile
was found between the IV and SC groups, with
the exception of a higher incidence of ISR for
the SC group, as would be expected [168 ISR in
the SC group (10.1% of patients) vs. 94 ISR in
the IV group (2.4%)]. However, ISR were all
deemed non-serious and did not require
treatment interruptions or discontinuation
[50]. The most common side effect described
in the studies was infection, particularly upper
Table 1 Safety summary (safety population)
Tocilizumab SC 162 mg
qw (n5 631) 289.82 PY
Tocilizumab IV 8 mg/kg
q4w (n5 631) 288.39 PY
AE
Total AE, n 1,747 1,697
Patients with[1 AE, n (%) 481 (76.2) 486 (77.0)
Discontinuation due to AE, n (%) 30 (4.8) 42 (6.7)
SAE
Total SAE, n 34 43
Patients with[1 SAE, n (%) 29 (4.6) 33 (5.2)
SAE per 100 PY (95% CI) 11.73 (8.12–16.39) 14.91 (10.79–20.08)
SI
Total SI 9 9
Patients with[1 SI, n (%) 9 (1.4) 9 (1.4)
SI per 100 PY (95% CI) 3.11 (1.25–5.89) 3.47 (1.66–6.38)
Serious hypersensitivity reactionsa, n (%) 2 (\1) 3b (\1)
ISR
Patients with ISR, n (%) 64 (10.1) 15 (2.4)
ISR, n 168 94
Erythema, n (%) 28 (4.4) 5 (0.8)
Pain, n (%) 12 (1.9) 5 (0.8)
Pruritus, n (%) 14 (2.2) 0(0)
Hematoma, n (%) 5 (0.8) 5 (0.8)
Dose interruption or study withdrawal because of ISR, n 0 0
Death, n (%) 0 (0) 1 (\1)
Reproduced from Burmester et al. [50] with permission from BMJ Publishing Group Ltd.
AE adverse event, ISRr injection site reaction, IV intravenous, PY patient-years, qwr every week, q4wr every 4 weeks, SAE
serious adverse event, SC subcutaneous, SI serious infection
a Serious hypersensitivity was deﬁned as an SAE occurring during or within 24 h of the injection or infusion, excluding ISR,
and evaluated as ‘related’ to study treatment by the investigator
b Of the three events in the tocilizumab IV group, one was cellulitis and one was retinal artery occlusion; these two events
were not considered consistent with a serious hypersensitivity reaction
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respiratory tract infection (7.3% TCZ SC and
11.6% TCZ IV). Serious infections were rare, but
reported in both groups (pneumonia—two cases
in each group). Septic arthritis occurred in two
patients in the IV group, with one case
progressing to sepsis and death. No deaths
were reported in the SC group (0/631; 1/631 in
the IV group). The most common cause for
study discontinuation due to side effects was
infection in both groups (1.1% TCZ SC and
1.3% TCZ IV).
The use of TCZ leads to a strong decrease in
C-reactive protein: this makes the clinical
evaluation of patients with a possible septic
disorder much more difficult. Other well-
recognized side effects of TCZ are its effects on
liver function tests (LFTs), neutrophils, and
cholesterol levels. Raised LFTs were seen in the
SUMMACTA, as well as BREVACTA trials. No
differences between groups were observed for
alanine-transaminase (ALT) and aspartate-
transaminase (AST) rises from normal to a
value more than three times the upper limit of
normal which occurred in 4.8 vs. 5.1% of
patients for ALT and 1 vs. 1.3% for AST, in the
SC and IV TCZ groups, respectively [50].
Neutropenia[1,000 9 109/L was reported in
a slightly higher proportion in the SC group
compared to the IV group (32.8 vs. 23.3%);
however, there was no difference between
groups with regard to severe neutropenia
(\1,000 9 109/L), 2.7 and 3.2%, respectively.
Increases in total cholesterol levels were also
more frequent in the SC group compared to the
IV group (23.8 vs. 20.6%), but with similar
proportions between groups with regard to rises
in low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol, and
triglyceride levels [50].
The BREVACTA trial showed similar safety
findings, with respiratory infections being the
most common side effects, 6.4% in each group
[51]. The most common ISR were erythema,
pruritus, and pain, and the proportion was
higher in the SC TCZ group compared to the
placebo group (7.1 and 4.1%, respectively). No
anaphylaxis or serious hypersensitivity
reactions were reported. Only 6.3% of patients
discontinued SC TCZ due to adverse events
(most commonly due to infections and raised
LFTs).
Infection was reported as the most common
serious adverse event (2.1% in the SC TCZ group
vs. 1.8% in the placebo group). Three deaths (3/
437) were reported by week 24, all in the SC TCZ
group (one death attributable to hemophilus
influenza sepsis, one to sepsis with
pancytopenia likely of gastrointestinal origin,
and one to lower respiratory tract infection). No
gastrointestinal perforation was reported up to
week 24, although one event of diverticular
hemorrhage was described in the SC TCZ group,
in a patient with a history of diverticular
bleeding. All patients were screened for TB and
those with active TB were excluded.
In patients who experienced elevated LFTs,
most had an increase less than three times the
upper limit of normal, with shifts occurring
more frequently in the SC TCZ group compared
to the placebo group (33 vs. 13%). Patients
experienced a decreased neutrophil count
([1,000/mm3) in a higher proportion in the
SC TCZ group (16.7 vs. 3.7%), while severe
neutropenia (\1,000/mm3) was only registered
in the SC TCZ group (3.7%). No events of severe
thrombocytopenia (\50,000/mm3) occurred.
The proportion of patients with cholesterol
level shifts from \200 mg/dL at baseline to
C200 mg/dL was higher in the SC TCZ group
compared to the placebo group (45 and 14%,
respectively). Increases in low-density
lipoprotein cholesterol and triglyceride levels
also occurred more frequently in the SC TCZ
group compared to the placebo group.





Current guidelines recommend that newly
diagnosed patients with moderate to severe RA
are commenced on a combination of DMARDs,
usually hydroxychloroquine and methotrexate
or possibly MTX monotherapy [34, 36]. The
most important element of treatment, however,
is that patients are seen and started on
immunosuppression as early as possible, to
optimize outcomes [57].
In the UK, patients with persistently high
disease activity (two DAS 28 scores [5.1 at
least 1 month apart) who have failed at least
two conventional DMARDs trialed
(including MTX) for a minimum of
6 months at the standard dose (or less if
treatment resulted in side effects) may
qualify for biologic therapy (see Fig. 2).
According to the National Institute for
Health and Care Excellence (NICE) and
European League Against Rheumatism
(EULAR) recommendations, three classes of
biologic agents can be given as first line to
patients with active RA:
Fig. 2 NICE rheumatoid arthritis clinical treatment path-
way. ABA abatacept, AE adverse events, CI contraindica-
tions, DAS 28 Disease Activity Score in 28 Joints, DMARD
disease-modifying antirheumatic drug, MTX methotrexate,
NICE National Institute for Health and Care Excellence,
RA rheumatoid arthritis, TCZ tocilizumab, TNF tumor
necrosis factor
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1. Anti-TNF a, with a choice of five agents
(adalimumab, etanercept, golimumab,
certolizumab, and infliximab), all of which
are available by SC apart from infliximab
which is administered by IV infusion;
2. Abatacept (available both by IV and SC);
3. TCZ, (available both by IV and SC).
NICE guidelines follow European Commission
and Food and Drug Administration (FDA)
approval of SC TCZ for the treatment of
moderate to severe RA in patients who are
either intolerant to or have failed to respond to
other RA treatments, in April and October 2013,
respectively. This approval made TCZ the first
anti-IL-6 receptor biologic available as SC and
IV formulations for both mono and
combination therapy with MTX [58]. TCZ can
also be given as third line for patients with RA,
after failure/intolerance to anti-TNF a and RTX,
or as second line, if contraindications to RTX




The advantages of SC formulations include
convenience and reduced cost compared with
IV therapies. Time off work or usual activities to
attend pre-booked IV infusions requires
significant infrastructure and is not patient
focused. Self-administration (following
appropriate training) is ideal for many patients
such as those with full-time work
commitments, child care issues, and who
travel frequently. Overall, patients tend to
have a preference for SC over IV
administration of medications [59–61].
However, there are patients for whom IV
administration is more suitable. These include
patients with extensive hand deformities or
who have needle phobia, and those where
there is concern regarding drug compliance.
Regardless, close monitoring of patients
should be undertaken in all cases paying
particular attention to the full blood count,
liver enzymes, and cholesterol levels. The
British Society for Rheumatology (BSR) has
published national guidelines for patients
receiving IV TCZ, although local policies may
differ [62]. The IV TCZ guidelines for patients
with RA will be used as a proxy for monitoring
the SC TCZ formulation. In addition, as
neutropenia and cholesterol level shifts are
more frequent in the SC group, we suggest
that closer monitoring of these parameters
should be performed for patients prescribed SC
formulation. The summary of
recommendations is as follows:
1. Baseline fasting lipid profile (if abnormal,
treatment should be given in accordance
with local guidelines); lipid profile should
be repeated in 3 months and treatment
instituted/altered if appropriate.
2. Four-weekly monitoring of the absolute
neutrophil count for the first 6 months,
then less frequently if severe neutropenia
does not occur.
3. Four-weekly monitoring of LFTs for the first
6 months (and every 2–3 months thereafter
if stable), caution when using other
hepatotoxic drugs, and education with
regard to reducing alcohol consumption.
4. Four-week interruption of TCZ prior to
elective joint replacement surgery, to
reduce the risk of post-operative infection.
TCZ can be restarted once infection is
excluded and the wound has healed.
5. TCZ should be stopped at least 3 months
prior to planned conception and should not
be given to women who breastfeed.
6. Annual influenza vaccine and
pneumococcal vaccination are
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recommended and should be encouraged,
while live attenuated vaccines are
contraindicated.
7. TCZ should be used with caution in patients
who have a history of diverticulitis, or are
taking corticosteroids and/or NSAIDs, due
to the risk of gastro-intestinal perforation.
TOCILIZUMAB MONOTHERAPY
IN RHEUMATOID ARTHRITIS
It would appear that there is an advantage in
using TCZ as monotherapy compared with
other biologic agents [63]. This has particular
relevance as MTX is poorly tolerated in a
substantial number of patients [40].
The AMBITION trial (ClinicalTrials.gov
#NCT00109408) compared TCZ monotherapy
(8 mg/kg every 4 weeks) with MTX
monotherapy in patients with active RA
(including a high proportion of patients with
early disease) over 24 weeks [52]. Results
showed superiority of TCZ monotherapy, with
a significant improvement in disease signs and
symptoms. The weighted difference for ACR 20
response at week 24 was 0.19 (95% CI
0.11–0.27, P\0.001). TCZ was also superior to
placebo at week 8 (ACR 20 remission: 55.6 vs.
13.1%) with a weighted difference of 0.43. The
superiority of TCZ was also seen in MTX-naive
patients (ACR 20 remission: 53.7 vs. 68.6%; ACR
50 remission: 33.2 vs. 45%; ACR 70 remission:
14.2 vs. 27.2% in the MTX and TCZ groups,
respectively).
DAS 28 at week 24 also improved in a higher
proportion in the TCZ group compared to MTX
group (adjusted mean change from baseline:
-3.31 vs. -2.05) and the proportion of patients
in remission at week 24 (DAS 28\2.6) was
higher in the TCZ group (32 vs. 4%). An
increase in hemoglobin (Hb) levels was seen in
the TCZ group (by 1.19 g/dL from baseline),
more so than in the MTX group, with an
increase only by 0.10 g/dL at week 24.
Normalization of mean Hb (from a level less
than the lower limit of normal at baseline)
occurred in the TCZ group by week 6, and the
effect was maintained to week 24. This effect
was not seen in the MTX group. Patients in the
TCZ group also had a greater improvement in
physical function as measured by HAQ-DI (-0.7
vs. -0.5 from baseline). This is the only study to
date which has shown clinical superiority of a
biologic agent given as monotherapy compared
with MTX monotherapy [52].
In addition, the recently published ADACTA
trial, a head-to-head monotherapy trial
comparing TCZ with adalimumab (ADA) in
patients with active RA who had failed or
developed side effects to MTX, showed
superiority of TCZ monotherapy (DAS 28
mean change from baseline: -3.3 in the TCZ
group vs. -1.8 in the ADA group, difference
-1.5, 95% CI -1.8 to -1.1; P\0.0001) [64].
Starting with week 16, more patients in the TCZ
group received ACR and EULAR remission [33],
compared to the ADA group (in ADACTA).
Physical function as assessed by the HAQ-DI
score improved more significantly in the TCZ
group than in the ADA group (change from
baseline to week 24: -0.7 vs. -0.5; difference
between adjusted means: -0.2, 95% CI -0.3 to
0.0; P = 0.0653). The proportion of patients
with HAQ-DI improvement of at least 0.22
from baseline to week 24 was higher in the
TCZ group compared to the ADA group (56.4 vs.
51.2%). This data suggest that TCZ is a
preferable biologic agent for patients with
active RA who are intolerant to traditional
DMARDs [36].
The MUSASHI trial (ClinicalTrials.jp
#JapicCTI-101117), a recent phase III study on
Japanese patients, assessed the efficacy and
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safety of SC vs. IV TCZ monotherapy in patients
with RA [65]. The study met its primary end
point, demonstrating the non-inferiority of TCZ
SC monotherapy to TCZ IV monotherapy. The
ACR 20 response rate at week 24 was achieved
in 79.2% (95% CI 72.9, 85.5) of patients in the
SC group and 88.5% (95% CI 83.4, 93.5) in the
IV group (weighted difference -9.4% [95% CI
-17.6, -1.2]).
ACR 50 and ACR 70 response rates at week 24
were also similar between groups. DAS
28-erythrocyte sedimentation rate (ESR),
Clinical Disease Activity Index (CDAI), and
Boolean Index remission rates at week 24 were
49.7, 16.4, and 15.7%, respectively, in the SC
group, and 62.2, 23.1, and 16.0%, respectively,
in the IV group. DAS 28-ESR low disease activity
at week 24 was achieved in a higher proportion
in the IV group (82.1% [95% CI 76.0, 88.1])
than in the SC group (65.4% [95% CI 58.0,
72.8]). Physical function improvement was
assessed by HAQ-DI and defined as a change of
-0.3 units from baseline at week 24. This was
56.6% (95% CI 48.9, 64.3) and 67.9% (95% CI
60.6, 75.3) in the SC and IV groups,
respectively.
The safety profiles were comparable between
groups, with the exception of ISRs, which
occurred more frequently in the SC group
than in the IV group. Over 24 weeks, AEs
occurred in 89.0% (154/173) and 90.8% (157/
173), SAEs in 7.5% (13/173) and 5.8% (10/173),
adverse drug reactions in 83.2% (144/173) and
86.1% (149/173) of patients, and serious adverse
drug reactions in 3.5% (6/173) and 5.8% (10/
173) of patients in the SC and IV groups,
respectively. No deaths or malignancies were
reported.
Infections were reported in 41.6 and 45.1%
of patients in the SC and IV groups,
respectively. Nasopharyngitis was the most
common event (17.9% in the SC group and
20.8% in the IV group). Serious infections
(herpes zoster, pneumonia, cellulitis,
gastroenteritis) occurred in 1.2% of patients in
the SC group and in 2.9% of patients in the IV
group. ISRs were reported in 12.1% of patients
in the SC group and in 5.2% in the IV group
(placebo injection). All ISRs were mild and no
cases resulted in discontinuation from the
study. One patient (0.6%) in the IV group had
an anaphylactic reaction after the second
infusion and was withdrawn from the study.
There were no cases of serious hypersensitivity
in the SC group. The proportion of patients
experiencing elevations in lipid levels and LFTs
was similar between groups. Increases in total
cholesterol from \200 mg/dL at baseline to
C200 mg/dL occurred in 56.1 and 53.7% of
cases in the SC and IV groups, respectively.
Grade 1 and 2 shifts in ALT and AST were
reported in 22.5% of patients in both SC and IV
groups (ALT) and 12.8 versus 18% in the SC and
IV groups, respectively (AST). Grade 3 shifts
were rare (1 patient in the SC group and 2
patients in the IV group for ALT, 1 patient in the
SC group for AST). There were no grade 4 shifts
in LFTs reported. A proportion of 2.9% of
patients experienced grade 3 neutropenia
(500–1,000 cells/mm3) in each group, with 1
patient in the SC group being withdrawn from
the study. No grade 4 neutropenia (\500/mm3)
was reported.
CONCLUSION
Following the success of IV TCZ, the arrival of
SC TCZ is a welcome addition to the arsenal to
combat the morbidity and premature mortality
associated with RA. The efficacy of SC TCZ in
both monotherapy and combination therapy
and the acceptable safety profile are reassuring;
however, longer-term data are required. Certain
groups of patients may benefit, especially those
Rheumatol Ther (2015) 2:17–31 27
intolerant to traditional DMARDs. Increasingly,
SC TCZ will be incorporated into management
paradigms to optimize the outcomes for all RA
patients.
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